S&P Futures
4,132.25 +8.75 (+0.21%) Dow Futures
33,951.00 +17.00 (+0.05%) Nasdaq Futures
12,571.50 +56.00 (+0.45%) Russell 2000 Futures
1,967.70 +2.60 (+0.13%) Crude Oil
75.31 +1.20 (+1.62%) Gold
1,887.50 +8.00 (+0.43%)
Pre-Market:
Chart Events
Performance Outlook
| Previous Close | 164.61 |
| Open | 164.55 |
| Bid | 0.00 x 900 |
| Ask | 163.60 x 800 |
| Day's Range | 163.10 - 164.85 |
| 52 Week Range | 155.72 - 186.69 |
| Volume | |
| Avg. Volume | 7,080,273 |
| Market Cap | 427.101B |
| Beta (5Y Monthly) | 0.56 |
| PE Ratio (TTM) | 28.86 |
| EPS (TTM) | 5.66 |
| Earnings Date | Apr 17, 2023 - Apr 21, 2023 |
| Forward Dividend & Yield | 4.52 (2.62%) |
| Ex-Dividend Date | Nov 21, 2022 |
| 1y Target Est | 183.80 |
- Financial Times
The jig is up for the Texas two-step
Today is Tuesday, February 7th, and this is your FT News Briefing. Johnson & Johnson can no longer sidestep certain liability lawsuits. Google is playing catch-up with its artificial intelligence technology.
- Benzinga
Johnson & Johnson's Drug Acquired Via Momenta Deal Shows Encouraging Data In Fetal Disorder
Janssen, a unit of Johnson & Johnson (NYSE: JNJ), announced topline results from the proof-of-concept Phase 2 open-label UNITY trial for pregnant adults at high risk for severe hemolytic disease of the fetus and newborn. In 2020, Johnson & Johnson shelled out $6.5 billion to acquire Momenta Pharmaceuticals Inc, gaining access to its lead product, nipocalimab. HDFN is a rare condition that can cause life-threatening anemia in the fetus. It occurs when the blood types of a pregnant individual and
- Zacks
Biotech Stocks' Q4 Earnings Due on Feb 7: VRTX, INCY and EXEL
Let us take a look at what is in store for some of the biotech stocks VRTX, INCY and EXEL, which are scheduled to report on Feb 7.
